18 Aug Half Year Update
Investor meeting at 13:00 BST / 14:00 CEST Paris, France and Camberley, UK – 18 August 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces...
10 Aug Boosting reassurance for international travel through reliable COVID-19 testing
As international travel begins to re-open following the challenges of the COVID-19 pandemic, there’s a growing need for reliable, high-quality tests to satisfy the border requirements of different countries. The travel...
05 Aug Notice of investor meeting
Posted at 07:00h
in Uncategorized
Paris, France and Camberley, UK – 5 August 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), a leading international specialist in clinical diagnostics, announces that it will hold an investor...
29 Jul David Allmond announced as CEO following decision by Graham Mullis to retire
Paris, France and Camberley, UK – 29 July 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), a leading international specialist in clinical diagnostics, announces the appointment of David Allmond as...
14 Jul Overwhelmed by COVID-19, are other serious infectious diseases neglected?
The costs and healthcare challenges of tackling COVID-19 have threatened the world’s ability to address a steady rise in other serious infectious diseases. That’s the conclusion of a panel of experts...
06 Jul Director/PDMR Shareholding
Posted at 17:09h
in Novacyt Group
Paris, France and Camberley, UK – 06 July 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on...
29 Jun Expansion of PathFlow® COVID-19 lateral flow test portfolio
Posted at 07:06h
in Uncategorized
Paris, France and Camberley, UK – 29 June 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is to launch two PathFlow® COVID-19 antigen lateral...
29 Jun Publication of Annual Report
Posted at 07:04h
in Uncategorized
Paris, France and Camberley, UK – 29 June 2021 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company's Annual Report and...
24 Jun Don’t let COVID-19 distract you from a rise in other infectious diseases – stay alert!
The growth of the COVID-19 pandemic globally over the past 18 months has been exponential, and despite mitigating measures and the vaccine roll-out, the virus continues to mutate and spread. As...
22 Jun Full year 2020 results and update on growth strategy
Transformational performance in 2020Continued strong demand for COVID-19 testing in 2021Strategy to deliver long-term growth through test, instrument, and geographic expansion in key areas, supplemented by M&A https://novacyt.com/wp-content/uploads/2021/06/Novacyt-full-year-2020-results-Final-ENGLISH.pdf ...